Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 147 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French MOST POPULAR Tesco is making it even easier to support life-saving research February 3, 2023 Holiday Lights Are My Favorite Thing December 12, 2023 Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer June 30, 2025 ¿Puede el uso de un microondas causar cáncer? April 7, 2022 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Futibatinib The Nobel Prize winner helping us treat children’s cancers Lion With Skin Cancer Has Received Radiation Therapy In Hospital New Type of Chemotherapy Bypasses Healthy Cells to Decrease Negative Side...
